A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis

J. D. Bradley, D. Flusser, Barry Katz, H. R. Schumacher, K. D. Brandt, M. A. Chambers, L. J. Zonay

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Objectie. We evaluated the effectiveness and rapidity of onset of S-adenosylmethionine (SAM), administered as daily intravenous boluses of 400 mg for 5 days, followed by oral tablets, 200 mg thrice daily for 23 days, versus a matching placebo regimen, in the treatment of 81 patients with symptomatic knee osteoarthritis (OA). Methods. The study was bicentric, randomized, double blinded, and placebo controlled. Patients underwent a 7-day washout of arthritis medications prior to initiation of this study treatment. Major outcome measures were the Stanford Health Assessment Questionnaire disability and pain scales, and supplemental visual analog scales for rest and walking pain. Results. At one site, patients had milder OA, the baseline characteristics of the treatment groups were well matched, and the SAM treated group showed significantly greater reduction in overall pain and rest pain (p < 0.05) than the placebo treated group. At the other site, the patients had more severe OA, randomization yielded markedly different treatment groups, and the response to treatment did not differ between groups. Onset of SAM effect was seen as early as 14 days after the start of treatment. Conlusion. SAM may be an effective treatment for some patients with symptomatic knee OA, and merits further study. Intravenous loading before oral maintenance therapy may be advantageous.

Original languageEnglish
Pages (from-to)905-911
Number of pages7
JournalJournal of Rheumatology
Volume21
Issue number5
StatePublished - 1994

Fingerprint

S-Adenosylmethionine
Knee Osteoarthritis
Placebos
Pain
Therapeutics
Osteoarthritis
Random Allocation
Visual Analog Scale
Tablets
Walking
Arthritis
Outcome Assessment (Health Care)
Health

Keywords

  • Knee osteoarthritis
  • S-adenyosylmethionine

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis. / Bradley, J. D.; Flusser, D.; Katz, Barry; Schumacher, H. R.; Brandt, K. D.; Chambers, M. A.; Zonay, L. J.

In: Journal of Rheumatology, Vol. 21, No. 5, 1994, p. 905-911.

Research output: Contribution to journalArticle

Bradley, J. D. ; Flusser, D. ; Katz, Barry ; Schumacher, H. R. ; Brandt, K. D. ; Chambers, M. A. ; Zonay, L. J. / A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis. In: Journal of Rheumatology. 1994 ; Vol. 21, No. 5. pp. 905-911.
@article{7d5b916680ac43588fff6c2743c7c467,
title = "A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis",
abstract = "Objectie. We evaluated the effectiveness and rapidity of onset of S-adenosylmethionine (SAM), administered as daily intravenous boluses of 400 mg for 5 days, followed by oral tablets, 200 mg thrice daily for 23 days, versus a matching placebo regimen, in the treatment of 81 patients with symptomatic knee osteoarthritis (OA). Methods. The study was bicentric, randomized, double blinded, and placebo controlled. Patients underwent a 7-day washout of arthritis medications prior to initiation of this study treatment. Major outcome measures were the Stanford Health Assessment Questionnaire disability and pain scales, and supplemental visual analog scales for rest and walking pain. Results. At one site, patients had milder OA, the baseline characteristics of the treatment groups were well matched, and the SAM treated group showed significantly greater reduction in overall pain and rest pain (p < 0.05) than the placebo treated group. At the other site, the patients had more severe OA, randomization yielded markedly different treatment groups, and the response to treatment did not differ between groups. Onset of SAM effect was seen as early as 14 days after the start of treatment. Conlusion. SAM may be an effective treatment for some patients with symptomatic knee OA, and merits further study. Intravenous loading before oral maintenance therapy may be advantageous.",
keywords = "Knee osteoarthritis, S-adenyosylmethionine",
author = "Bradley, {J. D.} and D. Flusser and Barry Katz and Schumacher, {H. R.} and Brandt, {K. D.} and Chambers, {M. A.} and Zonay, {L. J.}",
year = "1994",
language = "English",
volume = "21",
pages = "905--911",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "5",

}

TY - JOUR

T1 - A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis

AU - Bradley, J. D.

AU - Flusser, D.

AU - Katz, Barry

AU - Schumacher, H. R.

AU - Brandt, K. D.

AU - Chambers, M. A.

AU - Zonay, L. J.

PY - 1994

Y1 - 1994

N2 - Objectie. We evaluated the effectiveness and rapidity of onset of S-adenosylmethionine (SAM), administered as daily intravenous boluses of 400 mg for 5 days, followed by oral tablets, 200 mg thrice daily for 23 days, versus a matching placebo regimen, in the treatment of 81 patients with symptomatic knee osteoarthritis (OA). Methods. The study was bicentric, randomized, double blinded, and placebo controlled. Patients underwent a 7-day washout of arthritis medications prior to initiation of this study treatment. Major outcome measures were the Stanford Health Assessment Questionnaire disability and pain scales, and supplemental visual analog scales for rest and walking pain. Results. At one site, patients had milder OA, the baseline characteristics of the treatment groups were well matched, and the SAM treated group showed significantly greater reduction in overall pain and rest pain (p < 0.05) than the placebo treated group. At the other site, the patients had more severe OA, randomization yielded markedly different treatment groups, and the response to treatment did not differ between groups. Onset of SAM effect was seen as early as 14 days after the start of treatment. Conlusion. SAM may be an effective treatment for some patients with symptomatic knee OA, and merits further study. Intravenous loading before oral maintenance therapy may be advantageous.

AB - Objectie. We evaluated the effectiveness and rapidity of onset of S-adenosylmethionine (SAM), administered as daily intravenous boluses of 400 mg for 5 days, followed by oral tablets, 200 mg thrice daily for 23 days, versus a matching placebo regimen, in the treatment of 81 patients with symptomatic knee osteoarthritis (OA). Methods. The study was bicentric, randomized, double blinded, and placebo controlled. Patients underwent a 7-day washout of arthritis medications prior to initiation of this study treatment. Major outcome measures were the Stanford Health Assessment Questionnaire disability and pain scales, and supplemental visual analog scales for rest and walking pain. Results. At one site, patients had milder OA, the baseline characteristics of the treatment groups were well matched, and the SAM treated group showed significantly greater reduction in overall pain and rest pain (p < 0.05) than the placebo treated group. At the other site, the patients had more severe OA, randomization yielded markedly different treatment groups, and the response to treatment did not differ between groups. Onset of SAM effect was seen as early as 14 days after the start of treatment. Conlusion. SAM may be an effective treatment for some patients with symptomatic knee OA, and merits further study. Intravenous loading before oral maintenance therapy may be advantageous.

KW - Knee osteoarthritis

KW - S-adenyosylmethionine

UR - http://www.scopus.com/inward/record.url?scp=0028289828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028289828&partnerID=8YFLogxK

M3 - Article

C2 - 8064733

AN - SCOPUS:0028289828

VL - 21

SP - 905

EP - 911

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 5

ER -